Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | FABP7 | O15540 | 2/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29511484 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL29409577 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31749859 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31355501 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL259018 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL4557019 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL1593608 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL4557247 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL31309927 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 | |
| SCHEMBL29634951 | 1.00 | KMT2A (0.63) | KMT2ASMN1; SMN2LMNAEPHX2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049904-A1 | IMMUNOSTIMULATORY COMPOSITIONS | MALCORP BIODISCOVERIES LIMITED (NZ) | 2025-02-13 | — | — | US | disclosed |
| CN-117736151-A | Ligand compound of E3 ubiquitin ligase CDC20 and application thereof | 南京奥瑞药业有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2023121483-A1 | IMMUNOSTIMULATORY COMPOSITIONS | VICTORIA LINK LIMITED (NZ) | 2023-06-29 | — | — | WO | disclosed |
| US-10864279-B2 | Linker-drug and antibody-drug conjugate (ADC) employing the same | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2020-12-15 | — | — | US | disclosed |
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-06-21 | — | — | US | disclosed |
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE (TW) | 2018-06-21 | — | — | US | disclosed |
| US-8895231-B2 | Patterning process and resist composition | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2014-11-25 | — | — | US | disclosed |
| US-8445450-B2 | Antithrombotic dual inhibitors comprising a biotin residue | MERCK SHARP & DOHME B.V. (NL) | 2013-05-21 | — | — | US | disclosed |
| US-8445450-B2 | Antithrombotic dual inhibitors comprising a biotin residue | MERCK SHARP & DOHME B.V. (NL) | 2013-05-21 | — | — | US | disclosed |
| US-20120245109-A1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | MSD OSS B.V. (NL) | 2012-09-27 | — | — | US | disclosed |
| US-8168595-B2 | Antithrombotic dual inhibitors comprising a biotin residue | Msd Oss B.V (NL) | 2012-05-01 | — | — | US | disclosed |
| US-20120058428-A1 | PATTERNING PROCESS AND RESIST COMPOSITION | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2012-03-08 | — | — | US | disclosed |
| EP-1830887-B1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | ORGANON NV (NL) | 2011-03-09 | — | — | EP | disclosed |
| EP-1830887-B1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | ORGANON NV (NL) | 2011-03-09 | — | — | EP | disclosed |
| EP-1991271-B1 | ANTICOAGULANT ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN LABEL | ORGANON NV (NL) | 2011-03-09 | — | — | EP | disclosed |
| EP-1991271-B1 | ANTICOAGULANT ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN LABEL | ORGANON NV (NL) | 2011-03-09 | — | — | EP | disclosed |
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | MERCK SHARP & DOHME B.V. (NL) | 2010-02-04 | — | — | US | disclosed |
| US-20100004186-A1 | Antithrombotic Dual Inhibitors Comprising A Biotin Residue | N.V. ORGANON (NL) | 2010-01-07 | — | — | US | disclosed |
| WO-2007042469-A2 | ANTICOAGULANT ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN LABEL | N.V. ORGANON (NL) | 2007-04-19 | — | — | WO | disclosed |
| WO-2006067173-A2 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | N.V. ORGANON (NL) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029582-A1 | Anticoagulant Antithrombotic Dual Inhibitors Comprising a Biotin Label | FGB, F13B, SERPINC1 | KMT2A 1936/4885SMN1; SMN2 4855/4885LMNA 328/4885 |
| US-20100004186-A1 | Antithrombotic Dual Inhibitors Comprising A Biotin Residue | SERPINC1, BRS3, TBXA2R | KMT2A 4368/4885SMN1; SMN2 3923/4885LMNA 1485/4885 |
| US-20250049904-A1 | IMMUNOSTIMULATORY COMPOSITIONS | CD69, PBK, GALK1 | KMT2A 1159/4885SMN1; SMN2 1866/4885LMNA 2182/4885 |
| US-20180169262-A1 | LINKER-DRUG AND ANTIBODY-DRUG CONJUGATE (ADC) EMPLOYING THE SAME | ADCY7, ADCY1, ADCY9 | KMT2A 1373/4885SMN1; SMN2 2854/4885LMNA 1496/4885 |
| US-20120245109-A1 | ANTITHROMBOTIC DUAL INHIBITORS COMPRISING A BIOTIN RESIDUE | TBXA2R, MC3R, BRS3 | KMT2A 4322/4885SMN1; SMN2 3851/4885LMNA 1800/4885 |
| US-10864279-B2 | Linker-drug and antibody-drug conjugate (ADC) employing the same | ADCY7, ADCY1, ADCY9 | KMT2A 1373/4885SMN1; SMN2 2854/4885LMNA 1496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.